These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16604298)

  • 1. Osteoprotegerin and bone mineral density in hemodialysis patients.
    Nakashima A; Yorioka N; Doi S; Takasugi N; Shigemoto K; Kohno N
    Osteoporos Int; 2006; 17(6):841-6. PubMed ID: 16604298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.
    Moldovan D; Rusu C; Potra A; Moldovan I; Patiu IM; Gherman-Caprioara M; Kacso IM
    Int Urol Nephrol; 2017 May; 49(5):895-901. PubMed ID: 28161839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density may be related to atherosclerosis in hemodialysis patients.
    Nakashima A; Yorioka N; Tanji C; Asakimori Y; Ago R; Usui K; Shigemoto K; Harada S
    Osteoporos Int; 2003 Jun; 14(5):369-73. PubMed ID: 12768278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
    Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients.
    Doi S; Yorioka N; Masaki T; Ito T; Shigemoto K; Harada S
    Ther Apher Dial; 2004 Aug; 8(4):335-9. PubMed ID: 15274686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study.
    Wu WT; Lee RP; Wang CH; Fang TC; Lin NT; Chen IH; Hsu BG
    J Womens Health (Larchmt); 2010 Apr; 19(4):785-90. PubMed ID: 20210559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
    Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
    Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
    Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
    Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral bone disorder and osteoporosis in hemodialysis patients.
    Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
    Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships of serum levels of insulinlike growth factors with indices of bone metabolism and nutritional conditions in hemodialysis patients.
    Nanba K; Nagake Y; Miyatake N; Nakao K; Akagi S; Sugimoto T; Yamasaki H; Oishi K; Ichikawa H; Makino H
    Nephron; 2001 Oct; 89(2):145-52. PubMed ID: 11549896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.
    Inaba M; Okuno S; Imanishi Y; Ueda M; Yamakawa T; Ishimura E; Nishizawa Y
    Osteoporos Int; 2005 May; 16(5):517-25. PubMed ID: 15322741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.
    Jiang JQ; Lin S; Xu PC; Zheng ZF; Jia JY
    Nephrology (Carlton); 2011 Aug; 16(6):588-94. PubMed ID: 21649792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
    Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
    Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
    Dai Y; Shen L
    Chin Med J (Engl); 2007 Nov; 120(22):2017-21. PubMed ID: 18067789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.